New PET tracer could light up brain tumors
NCT ID NCT03465618
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 study tests a new PET imaging tracer called 89Zr-cRGDY in 17 people with malignant brain tumors or pituitary adenomas. The tracer is given in a very small dose to see how it spreads and clears from the body. The goal is to improve brain tumor imaging, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (ultrasmall silica particle tracer)
- What this could lead to
- If successful, this imaging method could help doctors see brain tumors more clearly, potentially guiding future treatments.
- What could go wrong
- This is a very early, small study (17 people) testing a new tracer for the first time in humans. It is not designed to treat or cure cancer, and the tracer may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple dye help surgeons see brain tumors in real time?
- Mapping the hidden toll of brain radiation on young minds
- Could an ALS drug clear the fog of chemo brain?
- Electric field device tested for Hard-to-Treat brain tumor
- Surgical flap opens door to brain tumors in small safety trial
- New group program aims to boost Well-Being in brain cancer patients